Exercise or Pills? Vivus (VVUS) Investors are Banking on Pills...
Up)
The general consensus is that Vivus' (Nasdaq: VVUS) Qnexa is a ridiculous drug which won't be approved by the FDA.
Here are some of the principal arguments floating around the Twitter-sphere:
As can be seen, many people on Twitter -- who are non-professionals in the drug world, we assume -- think that Qnexa shouldn't replace good, old-fashioned exercise. However, Qnexa may also help folks who are extremely obese to the point of not being able to exercise right out of the gate could benefit.
Currently, Vivus shares are halted as the meeting progresses. To see initial analysis from the committee members on today's panel, click here.
Those stocks that might see upside on disapproval include Orexigen Therapeutics (Nasdaq: OREX) and Arena (Nasdaq: ARNA), which saw their submission for obesity pills rejected last year by the FDA.
On a lighter note, or should we say heavier, the general consensus is that McDonald's (NYSE: MCD), Yum! (NYSE: YUM), Coca-Cola (NYSE: KO), PepsiCo (NYSE: PEP), and Nestle (OTCBB: NSRGF) will see a surge upon approval.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Here are some of the principal arguments floating around the Twitter-sphere:
- Studies also have obese people exercising, too.
- Political pressure is the most powerful argeement in favor of Qnexa.
- For $15,000 per year (or whatever it costs), someone could hire a trainer/nutritionist to address the underlying layers of obesity.
As can be seen, many people on Twitter -- who are non-professionals in the drug world, we assume -- think that Qnexa shouldn't replace good, old-fashioned exercise. However, Qnexa may also help folks who are extremely obese to the point of not being able to exercise right out of the gate could benefit.
Currently, Vivus shares are halted as the meeting progresses. To see initial analysis from the committee members on today's panel, click here.
Those stocks that might see upside on disapproval include Orexigen Therapeutics (Nasdaq: OREX) and Arena (Nasdaq: ARNA), which saw their submission for obesity pills rejected last year by the FDA.
On a lighter note, or should we say heavier, the general consensus is that McDonald's (NYSE: MCD), Yum! (NYSE: YUM), Coca-Cola (NYSE: KO), PepsiCo (NYSE: PEP), and Nestle (OTCBB: NSRGF) will see a surge upon approval.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Coca-Cola (KO) is Poised to Pop with Focus on Organic Growth - Barron's
- Morgan Stanley (MS) Shares Pressured on Questionable Facebook (FB) Tactics; Hits Fresh 6-Month Low
- Corinthian Colleges (COCO) Bounces Off Intraday Lows into Close
Create E-mail Alert Related Categories
FDA, Insiders' BlogRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
